HeartSciences Profit Margin 2022-2025 | HSCS

Current and historical gross margin, operating margin and net profit margin for HeartSciences (HSCS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. HeartSciences net profit margin as of January 31, 2025 is 0%.
HeartSciences Annual Profit Margins
HeartSciences Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Information Systems $0.004B $0.000B
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction.
Stock Name Country Market Cap PE Ratio
Veeva Systems (VEEV) United States $35.134B 48.53
Tempus AI (TEM) United States $6.966B 0.00
Hims & Hers Health (HIMS) United States $6.050B 97.25
Inspire Medical Systems (INSP) United States $4.470B 86.83
IRhythm Technologies (IRTC) United States $3.223B 0.00
Privia Health (PRVA) United States $2.873B 215.27
Schrodinger (SDGR) United States $1.881B 0.00
Clover Health Investments (CLOV) United States $1.839B 0.00
Enovis (ENOV) United States $1.825B 11.29
Omnicell (OMCL) United States $1.418B 30.59
Phreesia (PHR) United States $1.409B 0.00
Azenta (AZTA) United States $1.154B 53.72
10x Genomics (TXG) United States $0.918B 0.00
Butterfly Network (BFLY) United States $0.568B 0.00
Fulgent Genetics (FLGT) United States $0.551B 0.00
Talkspace (TALK) United States $0.450B 267.00
Veradigm (MDRX) United States $0.449B 0.00
Standard BioTools (LAB) United States $0.440B 0.00
TruBridge (TBRG) United States $0.363B 0.00
Claritev (CTEV) United States $0.325B 0.00
Health Catalyst (HCAT) United States $0.270B 0.00
Nyxoah SA (NYXH) Belgium $0.206B 0.00
SOPHiA GENETICS SA (SOPH) Switzerland $0.189B 0.00
Pulmonx (LUNG) United States $0.182B 0.00
American Well (AMWL) United States $0.109B 0.00
EUDA Health Holdings (EUDA) Singapore $0.100B 0.00
Retrieve Medical Holdings (RMHI) United States $0.082B 0.00
MDxHealth SA (MDXH) Belgium $0.076B 0.00
P3 Health Partners (PIII) United States $0.066B 0.00
111 (YI) China $0.064B 0.00
CareCloud (CCLD) United States $0.060B 2.58
HeartBeam (BEAT) United States $0.055B 0.00
Outset Medical (OM) United States $0.040B 0.00
Zepp Health (ZEPP) China $0.039B 0.00
Zhongchao (ZCMD) China $0.030B 0.00
Bullfrog AI Holdings (BFRG) United States $0.016B 0.00
ImmunoPrecise Antibodies (IPA) Canada $0.014B 0.00
MSP Recovery (MSPR) United States $0.014B 0.00
Strata Skin Sciences (SSKN) United States $0.011B 0.00
Streamline Health Solutions (STRM) United States $0.010B 0.00
Healthcare Triangle (HCTI) United States $0.009B 0.00
Precipio (PRPO) United States $0.009B 0.00
Predictive Oncology (POAI) United States $0.008B 0.00
Movano (MOVE) United States $0.007B 0.00
Mobile-health Network Solutions (MNDR) Singapore $0.004B 0.00
Tivic Health Systems (TIVC) United States $0.002B 0.00
Syra Health (SYRA) United States $0.001B 0.00
Future Health ESG (FHLT) United States $0.000B 0.00